Home
Home

dulaglutide

Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide

Lilly's head-to-head with Victoza raises a red flag for diabetes drug dulaglutide
Fierce Biotech

Will Cymbalta Break Eli Lilly?

Will Cymbalta Break Eli Lilly?
Seeking Alpha

Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?

Can Diabetes Treatments Replace Patent Losses At Eli Lilly & Co?
Motley Fool

Eli Lilly Gains Slightly on Dulaglutide Data

Eli Lilly Gains Slightly on Dulaglutide Data
Yahoo/Zacks.com

Who loses most in Lilly vs. Novo diabetes study? AstraZeneca Read more: Who loses most in Lilly vs. Novo diabetes study? AstraZeneca - FiercePharma http://www.fiercepharma.com/story/who-loses-most-lilly-vs-novo-diabetes-study-astrazeneca/2014-02-26#ixz

Who loses most in Lilly vs. Novo diabetes study? AstraZeneca
Fierce Pharma

Clock Is Ticking For AstraZeneca

Clock Is Ticking For AstraZeneca
Forbes

Lilly weekly diabetes drug succeeds vs market leader Victoza -study

Lilly weekly diabetes drug succeeds vs market leader Victoza -study
Yahoo/Reuters

Could These Potential Catalysts Drive Lilly Higher?

Could These Potential Catalysts Drive Lilly Higher?
Motley Fool

Eli Lilly: 2014 Predictions

Eli Lilly: 2014 Predictions
Seeking Alpha

3 New Diabetes Drugs Possibly on the Way Soon

3 New Diabetes Drugs Possibly on the Way Soon
Motley Fool